Proliferative activity (MIB-1 index) is an independent prognostic parameter in patients with high-grade soft tissue sarcomas of subtypes other than malignant fibrous histiocytomas: A retrospective immunohistological study including 216 soft tissue sarcomas

Histopathology

Volumn 32, Issue 6, 1998, Pages 536-546

  Jensen, V ^a   Brandt Sorensen F ^a   Bentzen, S M ^a   Ladekarl, M ^a   Steen Nielsen, O ^a   Keller, J ^a   Jensen, O M ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Bcl 2; MIB 1 index; P53; Prognosis; Proliferation; Sarcoma

Indexed keywords

DOXORUBICIN; MONOCLONAL ANTIBODY KI 67; PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOLOGY; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

EID: 15644366857     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2559.1998.00425.x     Document Type: Article

References (48)

1. Enzinger FM, Weiss SW. Soft Tissue Tumors. 3rd edn. St. Louis: CV Mosby, 1995.
2. Michie BA, Black C, Reid RP, Barrett A, Hamblem DL. Image analysis derived ploidy and proliferation indices in soft tissue sarcomas: Comparison with clinical outcome. J. Clin. Pathol. 1994: 47; 443-447.
3. Tsujimoto M, Aozasa K, Ueda T, Morimura Y, Komatsubara Y, Doi T. Multivariate analysis for histologic prognostic factors in soft tissue sarcomas. Cancer 1988: 62; 994-998.
4. Quinn CM, Wright NA. Review. The clinical assessment of proliferation and growth in human tumors: evaluation of methods and application as prognostic variables. J. Pathol. 1990: 160; 93-102.
5. Linden MD, Torres FX, Kubus J, Zarbo RJ. Editorial. Clinical application of morphological and immunocytochemical assessments of cell proliferation. Am. J. Clin. Pathol. 1992: 97; S4-S13.
6. Hall PA, Woods AL. Review. Immunohistochemical markers of cellular proliferation: achievements, problems and prospects. Cell Tissue Kinet. 1990: 23; 505-522.
7. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. Histopathalogy 1990: 17; 489-503.
8. Gerdes J, Schwab U, Lemke H, Stein H. Production of amouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int. J. Cancer 1983: 31; 13-20.
9. Cattoretti G, Becker MHG, Key G et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB-1 and MIB-3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J. Pathol. 1992: 168; 357-363.
10. Kerr JFR, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br. J. Cancer 1972: 26; 239-257.
11. Kerr JFR, Winterford CM, Harmond BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994: 75; 2013-2026.
12. Korsmeyer SJ. Review. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992: 80; 879-886.
13. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991: 352; 345-347.
14. Jensen OM, Høgh J, Østgaard SE, Nordentoft AM, Sneppen O. Histopathological grading of soft tissue tumours. Prognostic significance in a prospective study of 278 consecutive cases. J. Pathol. 1991: 163; 19-24.
15. Alvegård TA, Sigurdsson H, Mouridsen H et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: A randomized trial of the Scandinavian sarcoma group. J. Clin. Oncol. 1989: 7; 1504-1513.
16. Weiss SW. Histological Typing of Soft Tissue Tumours, 2nd edn, Berlin, Heidelberg: Springer-Verlag, 1994.
17. Gundersell HJG. Notes on the estimation of the numerical density of arbitrary profiles: the edge effect. J. Microscop. 1977: 111; 219-223.
18. Kawai A, Nogushi M, Beppu Y et al. Nuclear immunoreaction of p53 in soft tissue sarcomas. Cancer 1994: 73; 2499-2505.
19. Taubert H, Wurl P, Meye A et al. Molecular and immunohistochemical p53 in liposarcoma and malignant fibrous histiocytoma. Cancer 1995: 76; 1187-1196.
20. Joensuu H, Pylkkanen L, Toikkanen S. Bcl-2 protein expression and long term survival in breast cancer. Am. J. Pathol. 1994: 145; 1191-1198.
21. Drobnjak M, Latres E, Pollack D et al. Prognostic implication of p53 nuclear overexpression and high proliferation index of Ki-67 in adult soft tissue sarcomas. J. Natl. Cancer Inst. 1994: 86; 549-554.
22. Ueda T, Oazasa K, Tsujimoto M et al. Prognostic significance of Ki-67 reactivity in soft tissue sarcomas. Cancer 1989: 63; 1607-1611.
23. Swanson SA, Brooks JJ. Proliferation markers Ki-67 and p105 in soft tissue lesions. Am. J. Pathol. 1990: 137; 1491-1500.
24. Choong PFM, Akerman M, Willén H et al. Prognostic value of Ki-67 expression in 182 soft tissue sarcomas. Proliferation - a marker of metastasis? APMIS 1994: 102; 915-924.
25. Rose DSC, Maddox PH, Brown DC. Which proliferation markers for routine immunohislology? A comparison of live antibodies. J. Clin. Pathol. 1994: 47; 1010-1014.
26. Weidner N, Moore DH, Vartanian R. Correlation of Ki-67 antigen expression with mitotic ligure index and tumor grade in breast carcinomas using the novel 'paraffin'-reactive MIB-1 antibody. Hum. Pathol. 1994: 25; 337-342.
27. Yang P, Hirose T, Hasegawa T, Seki K, Sano T, Hizawa K. Prognostic implication of the p53 protein and Ki-67 antigen immunohistochemistry in malignant fibrous histiocytoma. Cancer 1995: 76; 618-625.
28. Swanson SA, Brooks JJ. Proliferation markers Ki-67 and p105 in soft tissue lesions. Am. Pathol. 1990: 157; 1491-1500.
29. Choong PFM, Akerman M, Willén H et al. Expression of proliferating cell nuclear antigen (PCNA) and Ki-67 in soft tissue sarcoma. Is prognostic significance histotype-specific? APMIS 1995: 103; 797-805.
30. Latres K, Drobnjak M, Pollack D et al. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Am. J. Pathol. 1994: 145; 345-355.
31. Cordon-Cardo C, Latres E, Drobnjak M et al. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res. 1994: 54; 794-799.
32. Toffoli G, Doglioni C, Cernigoi C et al. p53 overexpression in human soft tissue sarcomas: relation to biological aggressiveness. Ann. Oncol. 1994: 5; 167-172.
33. Soini Y, Vahakangas K, Nuorva K, Kamel D, Lane DP, Pakko P. p53 immunohistochemistry in malignant librous histiocytomas and other mesenchymal tumours. J. Pathol. 1992: 168; 29-33.
34. Resnick JM, Cherwitz, D, Knapp D, Uhlman D, Niehans GA. A microwave method that enhances detection of aberrant p53 expression in formalin-fixed, paraffin-embedded tissues. Arch. Pathol Lab. Med. 1995: 119; 360-366.
35. Hall PA. Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? - revisited! Editorial. J. Pathol. 1994: 172; 1-4.
36. Wadayama B, Toguchida J, Yamaguchi T, Sasaki MS, Kotoura Y, Yamamuro T. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Br. J. Cancer 1993: 68; 1134-1139.
37. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumor types. Nature 1989: 342; 705-708.
38. Levine AJ, Momand J, Finlay CA. Review. The p53 tumour suppressor gene. Nature 1991: 351; 453-456.
39. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992: 358; 80-83.
40. Stratton MR, Moss S, Warren W et al. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Oncogene 1990: 5; 1297-1301.
41. Toguchida J, Yamaguchi T, Ritchie B et al. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Cancer Res. 1992: 52: 6194-6199.
42. Soini Y, Paakko P. bcl-2 is preferentially expressed in tumors of muscle origin but is not related to p53 expression. Histopathology 1996: 28; 141-145.
43. Hirakawa N, Naka T, Yamamoto I, Fukuda T, Tsuneyoshi M. Overexpression of bcl-2 protein in synovial sarcoma. Hum. Pathol. 1996: 27; 1060-1065.
44. Sreekantaiah C, Ladanyi M, Rodriqez E, Chaganti RSK. Review. Chromosomal aberrations in soft tissue tumors. Relevance to diagnosis, classilication, and molecular mechanisms. Am. J. Pathol. 1994: 144; 1121-1134.
45. Pezzella F, Morrison H, Jones M et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993: 22; 39-44.
46. Diehold J, Baretton G, Felchner M et al. bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas. Am. J. lin. Pathol. 1996: 105; 341-349.
47. Scotlandi K, Serra M, Manara MC et al. Clinical relevance of Ki-67 expression in bone tumors. Cancer 1995: 75; 806-814.
48. Wijsman JH, Jonker R, Keijzer R, Van De Velde CJH. Cornelisse CJ, Van Dierendonck JH. A new method to detect apoptosis in paraffin sections: in situ end-labelling of fragmented DNA. J. Histochem. Cytochem. 1993: 41; 7-12.